Branded aspirin sells without prescription, generic requires one

Branded aspirin is sold over the counter, but the generic requires a prescription

Why is the expensive, familiar box dispensed without a prescription while the cheaper generic version forces you to see a doctor? The discussion points to how Spain's Agency of Medicines and Medical Devices (AEMPS) authorizes each presentation separately. According to one participant, branded 500 mg acetylsalicylic acid has carried over-the-counter status since its registration, while many generics were registered as copies of reference presentations that did require a prescription — low doses for cardiovascular prevention, large packs — and inherited that label. Same molecule, different administrative regime and, on top of that, a different price.

The case is not an isolated one. The conversation also brings up paracetamol and 600 mg acetylcysteine as examples of the same asymmetry: some argue that the active ingredient requires a prescription while the branded version is sold without one. The discussion soon shifts to the role of pharmacies, the industry and the administration itself, with mutual accusations of usury, regulatory capture and ignorance of the rules. There is no consensus here: there are facts, the occasional outburst, and a question that hangs over the whole affair.

What the AEMPS says and why the generic inherits the prescription requirement

The key is that prescription or over-the-counter status is not decided by molecule, but by presentation. According to the thread's account, the AEMPS evaluates each authorization application and assigns the dispensing regime to each specific format. When a generic is registered as a copy of a pharmaceutical product that requires a prescription, it carries that condition over. It is not a commercial decision by the manufacturer nor a pharmacy conspiracy: it is the result of an administrative file that, according to this version, nobody has reviewed since.

Hence the paradox that opens the discussion: Bayer's Aspirin 500 mg, registered decades ago as an over-the-counter medicine, is sold without a prescription. A 500 mg acetylsalicylic acid generic, registered as a copy of a presentation that required a prescription, is not. The result is that consumers pay more for the brand and less for the generic, but can only get the latter with a prescription that, in practice, many doctors do not consider necessary.

Things get complicated when doses come into play. Presentations of 100 to 300 mg, aimed at cardiovascular prevention, require a prescription in almost all cases. Those of 500 mg, intended for occasional pain, do not. But the boundary is not clear-cut and varies by laboratory and registration date. That is why two boxes identical in composition can have different regimes.

Paracetamol and acetylcysteine: the other cases of the same asymmetry

The pattern repeats, according to several participants, with paracetamol. The long-established brand is dispensed without a prescription; the 1-gram generic, in many cases, requires one. The same happens, according to the thread, with 600 mg acetylcysteine: Fluimucil and several commercial brands are sold freely, while some generics from Kern Pharma, Mabo, Sandoz and Stada carry the status of prescription-only medicines. The list of over-the-counter presentations includes four Fluimucil, three Cinfamucol, two Normofludil, one Frionex, one Notus Mucus and four 600 mg acetylcysteines from different manufacturers. Seven of the twenty-nine marketed generics are sold without a prescription. The rest are not.

The explanation is the same again: the dispensing regime is set presentation by presentation, not by active ingredient. A generic is not a "generic" for administrative purposes: it is a pharmaceutical product with its own file. And that file can carry over an inherited condition that no longer makes clinical sense.

The pharmacy business and the shadow of regulatory capture

Two accusations cross in the conversation. The first points at pharmacies: that some do not stock 500 mg generics and offer the expensive brand as the only option. The second points higher: at the industry and the regulatory bodies, which are accused of conniving to keep prices high and dispensing conditions favorable to brands. Neither is proven, and it is worth saying so.

What is verifiable is that the system allows two identical products to have different regimes and different prices. And that the consumer, without pharmacological training, has no way of knowing why. The practical consequence is that whoever wants the cheap generic needs a prescription that, in many cases, is not clinically justified. And whoever does not have one, pays for the brand.

Some argue the problem lies with the AEMPS, which has not updated the files. Some point to the industry, which has no incentive to request the change. And some point to the regional health departments, which set prices and conditions. The result is the same: the user pays the difference.

Prices in Spain compared to other countries

One of the contributions to the debate focuses on price. According to this participant, prescription medicines in Spain are comparatively cheap. Paracetamol costs pocket change, and anyone who has tried to buy epilepsy medication in the Caribbean or the United States knows what a shock is. It is an argument that, in his view, partially dismantles the scam narrative: the Spanish system, with all its rigidities, keeps prices low for the patient.

But the argument does not answer the original question. A low price does not explain why the brand is sold freely and the generic is not. The complaint is not only about price: it is about coherence. And coherence, in this case, is conspicuously absent.

Self-medication and the antiestéticar of aspirin

The underlying issue is the eternal debate about self-medication. If 500 mg aspirin is sold without a prescription, why not the generic? If branded paracetamol is dispensed freely, what risk does the generic add? The official answer is that the dispensing regime does not depend on actual risk, but on the administrative file. And to the consumer, that is indistinguishable from arbitrariness.

At the opposite extreme, there are those who argue that self-medication is a risk and that the prescription is a necessary barrier. But a barrier applied asymmetrically does not protect: it only makes things more expensive. And it makes them more expensive precisely for those who choose the cheaper option.

Conclusion: a prescription for an aspirin

The aspirin case is a symptom, not an exception. A system that sets the dispensing regime presentation by presentation, without reviewing inherited files, produces results nobody defends: expensive brand without prescription, cheap generic with prescription. The AEMPS has the power to review those conditions. The industry has no incentive to request the change. And the consumer, meanwhile, pays the difference or goes to the doctor for a box of aspirin.

The next time someone is asked for a prescription for a generic aspirin, the answer is not "free market". It is a file from twenty years ago that nobody has bothered to update.